Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731886 · ClinicalTrials.gov registry record · Phase 4
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
A Phase 4 study of Multiple Myeloma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01731886 is a Phase 4 study of Multiple Myeloma that has completed, run by Columbia University. The registered enrollment target is 60 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01731886, a Phase 4 study of Multiple Myeloma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Lenalidomide
- PROCEDURE Autologous peripheral blood stem cell transplant
- PROCEDURE Stem cell collection
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-04-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01731886
The ClinicalTrials.gov registry entry for NCT01731886 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT01731886 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01731886 about?
NCT01731886 is a clinical study titled "Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma". The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respon...
What is the current status of trial NCT01731886?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-09. Estimated completion is 2017-04-11.
What conditions does trial NCT01731886 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01731886?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Autologous peripheral blood stem cell transplant (PROCEDURE), Stem cell collection (PROCEDURE).
Who is sponsoring clinical trial NCT01731886?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01731886 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.